Use and Delivery of Granulocyte Colony–Stimulating Factor in Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy—Single-Centre Experience

Abstract

Most of the g-csf used in breast cancer treatment during the study period was given for primary prophylaxis. A major reason for the decision to use g-csf appears to have been physician-perceived risk of febrile neutropenia. Delivery of g-csf by home-care nurses was well received by patients.